NIH Updates its Position on Ivermectin
NIH’s COVID-19 Treatment Guidelines Panel has issued a statement today, that:
“As such, the Panel has determined that there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
“Since the last revision of the Ivermectin section of the Guidelines, results from several randomized clinical trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as non-peer-reviewed manuscripts. Updates to the Ivermectin section that are underway will include discussion of these studies. Because many of these studies had significant methodological limitations and incomplete information, the Panel cannot draw definitive conclusions about the clinical efficacy of ivermectin for the treatment of COVID-19.”
NIH concludes from its current analysis that, “results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19.”
The previous position of NIH, dated August 27, recommended against Ivermectin.
“The COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial” stated then the NIH Panel, arguing that the “available clinical data on the use of ivermectin to treat COVID-19 are limited.”
https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/
Panel members are listed at this link:
https://www.covid19treatmentguidelines.nih.gov/panel-roster/
NIH has not yet updated its guidelines, which will include a discussion of the studies that were reviewed.
The move by NIH came after it was approached by both the FLCCC led by Professor Paul Marik and Dr Pierre Kory, and Dr Andrew Hill, from the University of Liverpool, who conducted a meta-analysis for a body associated with the WHO.
According to FLCCC (Frontline Covid-19 Critical Care), “This “neither for nor against” recommendation from the NIH is similar to the recommendations for monoclonal antibodies & convalescent plasma. To clarify: the NIH is no longer recommending against its use by doctors, so prescribers should now be willing to write for Ivermectin.”
FLCCC also stated: “Furthermore, the NIH indicated that their Treatment Guidelines Panel will review additional trials as they come in. This keeps open the possibility of a new assessment of their recommendation. Bottom line: This is VERY good news!”
This story may be updated with developments.
Watch our webinar with Professor Paul Marik
Discover the Ivermectin-based prevention and treatment protocol developed by Dr George Fareed.
Find out about the most recent study about the use of Ivermectin for prophylaxis.
